Raptor Pharmaceutical has launched Quinsair levofloxacin inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Germany and Denmark, the company said. According to Raptor, it plans to launch Quinsair in Canada and in additional European countries later this year.
Raptor acquired Quinsair, formerly called Aeroquin, in August 2015, and the product was approved in the EU in March 2015. The company recently announced that Quinsair has been granted QIDP status by the FDA.
Raptor Chief Commercial Officer Dave Happel commented, “Raptor is excited to offer a new, first-in-class inhaled antibiotic treatment option for the many patients and families living with cystic fibrosis and battling chronic bacterial lung infections. We are beginning the European launch of Quinsair in Germany and Denmark, and continue to pursue approval of Quinsair for CF patients in the United States. We are confident that Quinsair will be an important growth driver for Raptor. We expect Quinsair to increase our revenue base and enhance our long-term growth profile while leveraging our commercial and development expertise and our existing global infrastructure.”
Read the Raptor press release.
